abstract |
The present invention relates generally to methods of treating and diagnosing conditions mediated by IL-5 and eosinophil overproduction, and more particularly to mAb, Fab, chimeric and humanized antibodies. More specifically, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or fragment thereof. |